New autologous T cell therapy offers hope for children with brain tumors Pediatric brain cancer is extremely challenging to treat. Results from a Phase 1 cell therapy trial revealed encouraging long-term survival rates. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-17325?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8IDMRHx-2g04Pck9Qy8L1VELuou1b5_W1VczLhe7pDMm9nOcYc_M3ZD07cf9_tsa6S0Fv9C3OfKZyFBBDOS8VHC8aF2Q&_hsmi=427883198&utm_content=427883198&utm_source=hs_email In children, the most fatal cancers occur inside the brain. When a tumor grows in an area like the brainstem, like a diffuse intrinsic pontine glioma (DIPG), surgical removal risks damaging sensitive tissue that regulate essential functions like breathing. Even without surgery, treatment can still be highly invasive. Getting drugs across the blood-brain barrier often requires injections into the brain or cerebrospinal fluid, and chemotherapy is notoriously difficult for children to tolerate. Thus, patients are often stuck without good treatment options.